Furthermore, amongst currently available agents for the use of TTR amyloid disease, it is the only therapeutic that has a dual indication for both neuropathy and cardiomyopathy, which are found concomitantly in many, if not most, hereditary or variant TTR patients. This evidence concerns the gene TTR and neuropathy.